# Encore Capital Group Inc: financial statements, quarterly

ECPG · Nasdaq · CIK 1084961 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ecpg.md) · [Financials](/companies/ecpg/financials.md) · [Filings](/companies/ecpg/filings.md) · [Insiders](/companies/ecpg/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ecpg/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [19.9](/filings/0001084961-24-000100.md) | [19.7 d](/filings/0001084961-26-000009.md) | [20.4](/filings/0001084961-25-000056.md) | [21.1](/filings/0001084961-25-000097.md) | [22.8](/filings/0001084961-25-000116.md) | [20.5 d](/filings/0001084961-26-000009.md) | [22.5](/filings/0001084961-26-000039.md) | [22.3](/filings/0001084961-26-000058.md) | [22.2](/filings/0001084961-25-000116.md) | [21.4 d](/filings/0001084961-26-000009.md) | [20.6](/filings/0001084961-26-000039.md) | [18.2](/filings/0001084961-26-000058.md) |
| Operating income | $m | [75.5](/filings/0001084961-24-000100.md) | [(217) d](/filings/0001084961-26-000009.md) | [83.6](/filings/0001084961-25-000056.md) | [102](/filings/0001084961-25-000097.md) | [106](/filings/0001084961-25-000116.md) | [(134) d](/filings/0001084961-26-000009.md) | [129](/filings/0001084961-26-000039.md) | [151](/filings/0001084961-26-000058.md) | [173](/filings/0001084961-25-000116.md) | [173 d](/filings/0001084961-26-000009.md) | [184](/filings/0001084961-26-000039.md) | [187](/filings/0001084961-26-000058.md) |
| Interest expense | $m | [50.6](/filings/0001084961-23-000107.md) | [54.5 d](/filings/0001084961-24-000008.md) | [55.8](/filings/0001084961-24-000048.md) | [61.4](/filings/0001084961-24-000085.md) | [66.9](/filings/0001084961-25-000116.md) | [68.5 d](/filings/0001084961-26-000009.md) | [70.5](/filings/0001084961-26-000039.md) | [73.9](/filings/0001084961-26-000058.md) | [74.2](/filings/0001084961-25-000116.md) | [75.2 d](/filings/0001084961-26-000009.md) | [73.1](/filings/0001084961-26-000039.md) | [73.9](/filings/0001084961-26-000058.md) |
| Income tax | $m | [10.7](/filings/0001084961-24-000100.md) | [(0.9) d](/filings/0001084961-26-000009.md) | [7.3](/filings/0001084961-25-000056.md) | [10.3](/filings/0001084961-25-000097.md) | [10.1](/filings/0001084961-25-000116.md) | [15.3 d](/filings/0001084961-26-000009.md) | [13.7](/filings/0001084961-26-000039.md) | [19.3](/filings/0001084961-26-000058.md) | [25.2](/filings/0001084961-25-000116.md) | [21.2 d](/filings/0001084961-26-000009.md) | [25.5](/filings/0001084961-26-000039.md) | [18.8](/filings/0001084961-26-000058.md) |
| Net income | $m | [19.3](/filings/0001084961-24-000100.md) | [(271) d](/filings/0001084961-26-000009.md) | [23.2](/filings/0001084961-25-000056.md) | [32.2](/filings/0001084961-25-000097.md) | [30.6](/filings/0001084961-25-000116.md) | [(225) d](/filings/0001084961-26-000009.md) | [46.8](/filings/0001084961-26-000039.md) | [58.7](/filings/0001084961-26-000058.md) | [74.7](/filings/0001084961-25-000116.md) | [76.7 d](/filings/0001084961-26-000009.md) | [86.2](/filings/0001084961-26-000039.md) | [64.0](/filings/0001084961-26-000058.md) |
| Diluted EPS | $ per share | [0.79](/filings/0001084961-24-000100.md) | not reported | [0.95](/filings/0001084961-25-000056.md) | [1.34](/filings/0001084961-25-000097.md) | [1.26](/filings/0001084961-25-000116.md) | not reported | [1.93](/filings/0001084961-26-000039.md) | [2.49](/filings/0001084961-26-000058.md) | [3.17](/filings/0001084961-25-000116.md) | not reported | [3.86](/filings/0001084961-26-000039.md) | [2.81](/filings/0001084961-26-000058.md) |
| Basic EPS | $ per share | [0.82](/filings/0001084961-24-000100.md) | not reported | [0.98](/filings/0001084961-25-000056.md) | [1.35](/filings/0001084961-25-000097.md) | [1.28](/filings/0001084961-25-000116.md) | not reported | [1.96](/filings/0001084961-26-000039.md) | [2.50](/filings/0001084961-26-000058.md) | [3.22](/filings/0001084961-25-000116.md) | not reported | [3.97](/filings/0001084961-26-000039.md) | [2.97](/filings/0001084961-26-000058.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [145](/filings/0001084961-23-000107.md) | [158](/filings/0001084961-25-000011.md) | [173](/filings/0001084961-24-000048.md) | [251](/filings/0001084961-24-000085.md) | [247](/filings/0001084961-24-000100.md) | [200](/filings/0001084961-26-000009.md) | [187](/filings/0001084961-25-000056.md) | [173](/filings/0001084961-25-000097.md) | [172](/filings/0001084961-25-000116.md) | [157](/filings/0001084961-26-000058.md) | [227](/filings/0001084961-26-000039.md) | [183](/filings/0001084961-26-000058.md) |
| Total assets | $m | [4,760](/filings/0001084961-23-000107.md) | [4,630](/filings/0001084961-25-000011.md) | [4,687](/filings/0001084961-24-000048.md) | [4,817](/filings/0001084961-24-000085.md) | [4,994](/filings/0001084961-24-000100.md) | [4,790](/filings/0001084961-26-000009.md) | [4,970](/filings/0001084961-25-000056.md) | [5,191](/filings/0001084961-25-000097.md) | [5,258](/filings/0001084961-25-000116.md) | [5,340](/filings/0001084961-26-000058.md) | [5,451](/filings/0001084961-26-000039.md) | [5,565](/filings/0001084961-26-000058.md) |
| Total liabilities | $m | [3,562](/filings/0001084961-23-000107.md) | [3,694](/filings/0001084961-25-000011.md) | [3,733](/filings/0001084961-24-000048.md) | [3,829](/filings/0001084961-24-000085.md) | [3,946](/filings/0001084961-24-000100.md) | [4,022](/filings/0001084961-26-000009.md) | [4,151](/filings/0001084961-25-000056.md) | [4,295](/filings/0001084961-25-000097.md) | [4,305](/filings/0001084961-25-000116.md) | [4,363](/filings/0001084961-26-000058.md) | [4,416](/filings/0001084961-26-000039.md) | [4,487](/filings/0001084961-26-000058.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [1,199](/filings/0001084961-23-000107.md) | [937](/filings/0001084961-24-000085.md) | [954](/filings/0001084961-24-000048.md) | [988](/filings/0001084961-24-000085.md) | [1,048](/filings/0001084961-25-000116.md) | [767](/filings/0001084961-26-000058.md) | [819](/filings/0001084961-26-000058.md) | [896](/filings/0001084961-26-000058.md) | [953](/filings/0001084961-25-000116.md) | [977](/filings/0001084961-26-000058.md) | [1,035](/filings/0001084961-26-000058.md) | [1,079](/filings/0001084961-26-000058.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity, us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [53.6 d](/filings/0001084961-24-000100.md) | [36.8 d](/filings/0001084961-26-000009.md) | [51.0](/filings/0001084961-25-000056.md) | [35.7 d](/filings/0001084961-25-000097.md) | [45.9 d](/filings/0001084961-25-000116.md) | [23.5 d](/filings/0001084961-26-000009.md) | [45.3](/filings/0001084961-26-000039.md) | [9.5 d](/filings/0001084961-26-000058.md) | [81.6 d](/filings/0001084961-25-000116.md) | [16.8 d](/filings/0001084961-26-000009.md) | [82.3](/filings/0001084961-26-000039.md) | [(29.4) d](/filings/0001084961-26-000058.md) |
| Capital expenditure | $m | [7.3 d](/filings/0001084961-24-000100.md) | [8.0 d](/filings/0001084961-26-000009.md) | [6.9](/filings/0001084961-25-000056.md) | [7.4 d](/filings/0001084961-25-000097.md) | [6.2 d](/filings/0001084961-25-000116.md) | [8.6 d](/filings/0001084961-26-000009.md) | [7.0](/filings/0001084961-26-000039.md) | [6.3 d](/filings/0001084961-26-000058.md) | [6.0 d](/filings/0001084961-25-000116.md) | [6.9 d](/filings/0001084961-26-000009.md) | [4.9](/filings/0001084961-26-000039.md) | [8.4 d](/filings/0001084961-26-000058.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [25.9](/filings/0001084961-23-000107.md) | [24.9](/filings/0001084961-24-000048.md) | [24.3](/filings/0001084961-24-000085.md) | [24.4](/filings/0001084961-24-000100.md) | [24.5](/filings/0001084961-25-000056.md) | [24.1](/filings/0001084961-25-000097.md) | [24.4](/filings/0001084961-25-000116.md) | [24.3](/filings/0001084961-26-000039.md) | [23.6](/filings/0001084961-26-000058.md) | [23.5](/filings/0001084961-25-000116.md) | [22.3](/filings/0001084961-26-000039.md) | [22.8](/filings/0001084961-26-000058.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 21,209,366 at 2026-07-29, from the cover of the [10-Q filed 2026-08-05](/filings/0001084961-26-000058.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:32 ET. No prices; not investment advice.